CN118159304A - 放射性核素复合物的组合疗法 - Google Patents

放射性核素复合物的组合疗法 Download PDF

Info

Publication number
CN118159304A
CN118159304A CN202280069041.9A CN202280069041A CN118159304A CN 118159304 A CN118159304 A CN 118159304A CN 202280069041 A CN202280069041 A CN 202280069041A CN 118159304 A CN118159304 A CN 118159304A
Authority
CN
China
Prior art keywords
dota
weeks
subject
mci
radiopharmaceutical compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202280069041.9A
Other languages
English (en)
Chinese (zh)
Inventor
P·D·艾莫内
D·奇科
M·F·马里亚尼
E·佐罗
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis AG
Advanced Accelerator Applications SA
Original Assignee
Novartis AG
Advanced Accelerator Applications SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis AG, Advanced Accelerator Applications SA filed Critical Novartis AG
Publication of CN118159304A publication Critical patent/CN118159304A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/083—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins the peptide being octreotide or a somatostatin-receptor-binding peptide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/088—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins conjugates with carriers being peptides, polyamino acids or proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Physics & Mathematics (AREA)
  • Optics & Photonics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
CN202280069041.9A 2021-10-27 2022-10-27 放射性核素复合物的组合疗法 Pending CN118159304A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163272447P 2021-10-27 2021-10-27
US63/272,447 2021-10-27
PCT/IB2022/060331 WO2023073603A1 (en) 2021-10-27 2022-10-27 Combination therapy of radionuclide complex

Publications (1)

Publication Number Publication Date
CN118159304A true CN118159304A (zh) 2024-06-07

Family

ID=84365353

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202280069041.9A Pending CN118159304A (zh) 2021-10-27 2022-10-27 放射性核素复合物的组合疗法

Country Status (11)

Country Link
US (1) US20250387523A1 (enExample)
EP (1) EP4422701A1 (enExample)
JP (1) JP2024539952A (enExample)
KR (1) KR20240093832A (enExample)
CN (1) CN118159304A (enExample)
AU (1) AU2022374887A1 (enExample)
CA (1) CA3234495A1 (enExample)
IL (1) IL312106A (enExample)
MX (1) MX2024004961A (enExample)
TW (1) TW202332473A (enExample)
WO (1) WO2023073603A1 (enExample)

Also Published As

Publication number Publication date
US20250387523A1 (en) 2025-12-25
CA3234495A1 (en) 2023-05-04
WO2023073603A1 (en) 2023-05-04
AU2022374887A1 (en) 2024-04-11
TW202332473A (zh) 2023-08-16
MX2024004961A (es) 2024-05-08
JP2024539952A (ja) 2024-10-31
IL312106A (en) 2024-06-01
EP4422701A1 (en) 2024-09-04
KR20240093832A (ko) 2024-06-24

Similar Documents

Publication Publication Date Title
Henriksen et al. Significant antitumor effect from bone-seeking, α-particle-emitting 223Ra demonstrated in an experimental skeletal metastases model
US6635234B1 (en) Preparation and use of radium-223 to target calcified tissues for pain palliation, bone cancer therapy, and bone surface conditioning
Chakraborty et al. Comparative studies of 177Lu–EDTMP and 177Lu–DOTMP as potential agents for palliative radiotherapy of bone metastasis
Aft et al. Enhancing targeted radiotherapy by copper (II) diacetyl-bis (N 4-methylthiosemicarbazone) using 2-deoxy-D-glucose
JP4247110B2 (ja) 新規メタロポルフィリン及び放射線治療用放射線増感剤としてのそれらの使用
RU2160121C2 (ru) Агенты для лучевой терапии, содержащие олово-117m
Ferreira et al. Radiopharmaceuticals for bone metastasis therapy and beyond: a voyage from the past to the present and a look to the future
Dahle et al. Relative biologic effects of low-dose-rate α-emitting 227Th-rituximab and β-emitting 90Y-tiuexetan-ibritumomab versus external beam X-radiation
CN115702009A (zh) 用于放射性标记psma结合配体的方法及其试剂盒
US6685913B1 (en) Lipid soluble radioactive metal chelates for tumor therapy
WO2011149844A1 (en) Delivery of high dose therapeutic radioisotopes to bone
Ranjbar et al. Development of 153Sm/177Lu-EDTMP as a possible therapeutic complex
Bushnell et al. Assessment of hepatic toxicity from treatment with 90Y-SMT 487 (OctreoTher™) in patients with diffuse somatostatin receptor positive liver metastases
JP2026505341A (ja) 神経膠芽腫を治療するための方法
Chakraborty et al. Evaluation of; 177Lu-EDTMP in Dogs with Spontaneous Tumor Involving Bone: Pharmacokinetics, Dosimetry and Therapeutic Efficacy
US7709613B2 (en) Rhenium-188 and rhenium-186 for treatment of tumors expressing a Na+/I− symporter
AU2022374887A1 (en) Combination therapy of radionuclide complex
US20070140961A1 (en) Radiotherapeutic high specific activity tin-117m and methods of use
WO2025000035A1 (en) Methods for the diagnosis and/or treatment of neuroendocrine cancers
Choong et al. Formulation and Quality Control Studies of EDTMP Freeze-Dried Kit for the Preparation of 153Sm-EDTMP
Chakraborty et al. [sup. 177] Lu-EDTMP: a viable bone pain palliative in skeletal metastasis.
CN117731806A (zh) 放射性核素标记的地诺单抗、其前体化合物、制法和应用
Hoskin Radioisotope therapy for metastatic bone disease
CN1315208A (zh) 166ho－dtpa,其制备方法和它作为液体辐射源的应用
Areberg et al. Uptake and retention of {sup 191} Pt in patients undergoing therapy with cisplatin

Legal Events

Date Code Title Description
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination